IQVIA Prescription Data Reveals U.S. Biopharma Market: New Drug Launches Underwhelm, Biosimilars Gain Ground
Core Conclusion
U.S. total prescription volume grew just 1.2% year-over-year (week ending May 8, 2026). Four new drugs—BMY’s Cobenfy, GILD’s Yeztugo, VRTX’s Journavx, and JNJ’s Icotyde—are all tracking below the trajectory needed to hit consensus 2026 revenue estimates. Simultaneously, biosimilar penetration is accelerating: Stelara biosimilars now hold ~39% of TRx, and the Prolia biosimilar Jubbonti captured ~31%. For investors, this points to downside risk to consensus for BMY, VRTX, JNJ, and AMGN, while ABBV’s Skyrizi and Rinvoq deliver strong organic growth.
New Drug Launch Trajectories Fall Short
Cobenfy (BMY) reached ~3,160 weekly TRx, up from ~3,010. Consensus 2026 revenue of $296mn implies a required weekly volume of ~3,800 scripts (assuming ~$1,450 net price). The current gap is ~17%, and the drug still lags comparable atypical antipsychotics at similar post-launch stages. Investment implication: Consensus appears optimistic; further weakness in prescription data could lead to material downward revisions.
Journavx (VRTX): weekly TRx ~19,640. Consensus 2026 revenue of $241mn requires 1.2–2.1mn total prescriptions (12-day course, 50–70% GTN). Current GTN is estimated at 65–75%, meaning realized net revenue per script is lower than consensus assumes. Hospital channel (~45% of scripts) is undercounted by IQVIA. Investment implication: Consensus relies on both volume acceleration and better GTN; both are challenged.
Icotyde (JNJ): week 6 TRx ~140 after launching on March 18, 2026. Consensus 2026 U.S. revenue of $296mn implies 36,000–48,000 total scripts (0–25% GTN). Current weekly run-rate is less than 1% of the required cumulative volume. Early sampling friction may distort data, but the gap remains enormous. Investment implication: Near-zero probability of meeting consensus unless prescriptions surge dramatically.
Yeztugo (GILD): weekly TRx ~1,710 (oral + injectable). PrEP market growth is strong (+14% y/y) and Descovy maintains >45% share. Payment coverage is 95% with low prior-auth requirements, but revenue visibility is poor due to unclear